The ECE1 Knockout NCI-H1299 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ECE1 gene encoding endothelin-converting enzyme-1. This pool of edited human non-small cell lung carcinoma cells provides a versatile loss-of-function model for dissecting the roles of ECE1 in endothelin signaling. By eliminating wild-type ECE1 function, this model facilitates pathway analysis and drug target validation without genetic complementation.
The host cell line, NCI-H1299, is a human lung adenocarcinoma epithelial line established from a lymph node metastasis of a 43-year-old Caucasian male. These cells display aggressive growth characteristics, including high proliferation, migration, and invasiveness, and serve as a standard model for studying oncogenic pathways and therapeutic interventions in non-small cell lung cancer. Their metastatic origin makes them particularly suited to investigations of tumor progression and metastasis-associated signaling.
ECE1 encodes a transmembrane metalloprotease responsible for the proteolytic processing of big endothelin-1 into the mature vasoactive peptide endothelin-1, which then binds and activates the G protein-coupled receptors EDNRA and EDNRB. Receptor activation triggers G??q/11-mediated signaling through phospholipase C?? (PLC??), leading to intracellular calcium release and downstream activation of protein kinase C (PKC), extracellular signal-regulated kinase 1/2 (ERK1/2), and AKT. ECE1 expression is transcriptionally regulated by NF-??B, AP-1, Smad3, and hypoxia-inducible factor 1?? (HIF-1??) in response to cytokines such as TNF-??, TGF-??, and hypoxic conditions. Additionally, ECE1 interacts with PKC?? and ??-arrestin, and its product, endothelin-1, induces transcription of immediate-early genes like c-Fos and c-Jun through ERK1/2-dependent mechanisms.
In the NCI-H1299 background, ECE1-driven production of endothelin-1 establishes autocrine and paracrine loops that promote tumor cell proliferation, survival, and migration via the MAPK/ERK and PI3K/AKT pathways. Therefore, knockout of ECE1 in these cells abolishes mature endothelin-1 generation, disrupting downstream signaling cascades that are frequently hyperactivated in non-small cell lung cancer. This model enables researchers to isolate ECE1-dependent effects from other growth factor inputs, providing a defined system to evaluate the specific contribution of the endothelin axis to oncogenic phenotypes and to assess the dependency of lung adenocarcinoma cells on endothelin signaling.
The polyclonal knockout population is suitable for diverse functional studies, including screening of ECE1 inhibitors, investigating tumor microenvironment interactions, and exploring mechanisms of drug resistance. Compatible assay formats encompass Western blotting for ECE1 and phospho-ERK1/2, endothelin-1 ELISA to confirm loss of mature peptide, RT-qPCR for ECE1 and EDN1 transcripts, MTT proliferation assays, Transwell migration and invasion assays, and flow cytometric apoptosis analysis. By offering a genetically disrupted ECE1 background in a clinically relevant lung cancer model, this product supports both fundamental research on endothelin signaling and translational applications in oncology. For further technical information, please contact Ascent Research.
